Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-4 brigimadlin in advanced dedifferentiated liposarcoma
jRCT2071230107Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2024
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of brigimadlin in dedifferentiated liposarcoma (DDL) (2 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of TEAEs (any grade) and Occurrence of Grade ≥3 TEAEs. Started Mar 2024; status: active, not recruiting.
02
Drugs
brigimadlin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on jRCT2071230107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230107.